[go: up one dir, main page]

HK1133394A1 - Method to enhance tissue regeneration - Google Patents

Method to enhance tissue regeneration

Info

Publication number
HK1133394A1
HK1133394A1 HK10100429.9A HK10100429A HK1133394A1 HK 1133394 A1 HK1133394 A1 HK 1133394A1 HK 10100429 A HK10100429 A HK 10100429A HK 1133394 A1 HK1133394 A1 HK 1133394A1
Authority
HK
Hong Kong
Prior art keywords
tissue growth
tissue regeneration
enhance tissue
modulating
signaling pathways
Prior art date
Application number
HK10100429.9A
Other languages
English (en)
Inventor
Leonard I Zon
Trista E North
Wolfram Goessling
Original Assignee
Childrens Medical Center
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Gen Hospital Corp filed Critical Childrens Medical Center
Publication of HK1133394A1 publication Critical patent/HK1133394A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK10100429.9A 2006-10-20 2010-01-14 Method to enhance tissue regeneration HK1133394A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85320206P 2006-10-20 2006-10-20
US85335106P 2006-10-20 2006-10-20
PCT/US2007/082093 WO2008070310A2 (fr) 2006-10-20 2007-10-22 Procédé permettant d'améliorer la régénération tissulaire

Publications (1)

Publication Number Publication Date
HK1133394A1 true HK1133394A1 (en) 2010-03-26

Family

ID=39492923

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10100429.9A HK1133394A1 (en) 2006-10-20 2010-01-14 Method to enhance tissue regeneration

Country Status (9)

Country Link
US (3) US9402852B2 (fr)
EP (3) EP2679221B1 (fr)
JP (4) JP5426389B2 (fr)
AU (1) AU2007329725B2 (fr)
CA (1) CA2666972C (fr)
HK (1) HK1133394A1 (fr)
MX (1) MX2009004164A (fr)
RU (1) RU2480213C2 (fr)
WO (1) WO2008070310A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2480213C2 (ru) * 2006-10-20 2013-04-27 Чилдрен'З Медикал Сентер Корпорейшн Способ стимуляции регенерации тканей
ES2845641T3 (es) 2008-11-06 2021-07-27 Univ Indiana Res & Tech Corp Materiales y métodos para mejorar procedimientos de injerto funcionante de células madre hematopoyéticas
US9056085B2 (en) 2009-02-03 2015-06-16 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9051548B2 (en) 2009-02-03 2015-06-09 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
EP2499242B1 (fr) * 2009-11-15 2019-05-01 Indiana University Research&technology Corporation Procédés pour améliorer l'administration et la greffe de cellules souches comprenant l'identification de récepteurs de prostaglandine e2 spécifiques
WO2011109729A2 (fr) * 2010-03-05 2011-09-09 University Of Rochester Inhibition d'ep1
CA2824113C (fr) * 2011-01-13 2020-04-14 Scipharm Sarl Composition d'analogue de la prostacycline et procede pour ameliorer la greffe de cellules souches hematopoietiques
CN103958667A (zh) 2011-09-30 2014-07-30 蓝鸟生物公司 用于改善病毒转导的化合物
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
RU2559586C1 (ru) * 2014-06-10 2015-08-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ стимуляции регенерации резецированной печени дигидрокверцетином
AU2016296741A1 (en) 2015-07-21 2018-02-22 The Children's Medical Center Corporation PD-L1 expressing hematopoietic stem cells and uses
EP3413896B1 (fr) 2016-02-12 2021-03-17 Bluebird Bio, Inc. Compositions d'augmentation de vcn et ses procédés d'utilisation
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
WO2019152549A1 (fr) 2018-02-05 2019-08-08 Cedars-Sinai Medical Center Procédés d'utilisation thérapeutique d'exosomes et d'arn y
WO2020009503A1 (fr) * 2018-07-06 2020-01-09 주식회사 씨케이바이오텍 Composition pharmaceutique comprenant un dérivé d'indirubine comme ingrédient actif
AU2020267561A1 (en) * 2019-05-08 2021-12-23 Capricor, Inc. Therapeutically active cells and exosomes

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US704057A (en) 1901-10-21 1902-07-08 Sandford Northrop Expansible boring-tool.
DE69033584T2 (de) 1989-10-16 2001-03-08 Amgen Inc., Thousand Oaks Stammzellenfaktor
CA2168091A1 (fr) 1993-08-23 1995-03-02 Stephen L. Smith Croissance in vitro de precurseurs neutrophiles et de precurseurs de megacaryocytes dans un milieu exempt de serum
AU6125396A (en) 1995-06-07 1996-12-30 Novartis Ag Serum-free media for primitive hematopoietic cells and metho ds of use thereof
CA2262469C (fr) * 1996-08-16 2005-11-22 Genentech, Inc. Utilisation de polypeptides wnt
US6372796B1 (en) 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
GB9904281D0 (en) 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
RU2259830C2 (ru) * 1999-11-24 2005-09-10 Оно Фармасьютикал Ко., Лтд. Фармацевтическая композиция для лечения заболеваний, связанных с потерей костной массы
WO2003055989A2 (fr) 2001-12-21 2003-07-10 Mount Sinai Hospital Compositions cellulaires et procedes de preparation et d'utilisation associes
RU2205627C1 (ru) 2002-05-30 2003-06-10 Открытое акционерное общество "Косметическое объединение "Свобода" Крем для лица, выводящий токсины
ES2584606T3 (es) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microesferas que comprenden ONO-1301
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
BRPI0408061A (pt) * 2003-03-04 2006-02-14 Pfizer Prod Inc tratamento médico utilizando um agonista de receptores seletivos de ep 2
US20050054103A1 (en) 2003-03-07 2005-03-10 Tony Peled Expansion of renewable stem cell populations using modulators of PI 3-kinase
EP1613742A2 (fr) 2003-04-08 2006-01-11 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Cellules souches presentant une sensibilite accrue a un agent chimio-attractif, methodes de production et d'utilisation associees
WO2005028678A2 (fr) * 2003-06-06 2005-03-31 Wyeth Procedes et materiaux permettant d'identifier des agents modulant le remodelage osseux, et agents ainsi identifies
CA2570407C (fr) * 2003-06-25 2014-01-07 Ottawa Health Research Institute Procedes et compositions pour moduler la croissance et la differentiation des cellules souches
GB0324523D0 (en) * 2003-10-21 2003-11-26 Medical Res Council Compositions and methods of treatment
US20050153887A1 (en) * 2003-10-24 2005-07-14 California Institute Of Technology Compositions for inducing cell growth and differentiation and methods of using same
US8309608B2 (en) 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005123191A1 (fr) * 2004-06-21 2005-12-29 Pharmacia & Upjohn Company Llc Inhibiteurs de pyk2 pour la stimulation de la fonction de l'osteoblaste
CA2573176A1 (fr) 2004-07-09 2006-01-19 Bc Cancer Agency Fusions de nup98-hox pour expansion de cellules souches hematopoietiques
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
WO2006078886A2 (fr) * 2005-01-18 2006-07-27 Irm Llc Composes et compositions utilises comme modulateurs de la voie de signalisation wnt
US20090104159A1 (en) 2005-02-10 2009-04-23 Felipe Prosper Vascular/Lymphatic Endothelial Cells
WO2007117262A2 (fr) 2005-07-29 2007-10-18 Athersys, Inc. Culture de cellules non embryonnaires à haute densité cellulaire
GB2447191B (en) 2005-12-22 2011-08-03 Es Cell Int Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
WO2007148332A1 (fr) 2006-06-22 2007-12-27 Yeda Resaerch And Development Co. Ltd Modulation du récepteur de la catécholamine
WO2008021475A2 (fr) 2006-08-16 2008-02-21 The General Hospital Corporation Compositions et procédés pour l'expansion de cellules souches hématopoïétiques ou la modulation de l'angiogenèse
RU2480213C2 (ru) * 2006-10-20 2013-04-27 Чилдрен'З Медикал Сентер Корпорейшн Способ стимуляции регенерации тканей
WO2008056963A1 (fr) 2006-11-10 2008-05-15 Chanil Moon Procédé permettant la prolifération de cellules souches au moyen de leptine

Also Published As

Publication number Publication date
JP2016121180A (ja) 2016-07-07
RU2480213C2 (ru) 2013-04-27
WO2008070310A2 (fr) 2008-06-12
AU2007329725A1 (en) 2008-06-12
CA2666972C (fr) 2015-12-29
CA2666972A1 (fr) 2008-06-12
EP3824885A1 (fr) 2021-05-26
US20210077505A1 (en) 2021-03-18
US9402852B2 (en) 2016-08-02
JP5426389B2 (ja) 2014-02-26
JP2014065723A (ja) 2014-04-17
EP2679221A1 (fr) 2014-01-01
US10736906B2 (en) 2020-08-11
RU2009118942A (ru) 2010-11-27
WO2008070310A3 (fr) 2008-12-18
US20160354385A1 (en) 2016-12-08
EP2077826B1 (fr) 2013-09-04
EP2077826A4 (fr) 2010-05-26
EP2077826A2 (fr) 2009-07-15
JP2010507592A (ja) 2010-03-11
JP2019189661A (ja) 2019-10-31
MX2009004164A (es) 2009-10-13
US20110009370A1 (en) 2011-01-13
EP2679221B1 (fr) 2020-09-23
AU2007329725B2 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
HK1133394A1 (en) Method to enhance tissue regeneration
UY39128A (es) Composiciones y métodos para modular la senda de señalización de wnt
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
WO2007092190A3 (fr) Procedes et compositions permettant de moduler l&#39;activite du recepteur du sphingosine-1-phosphate (s1p)
WO2010025295A3 (fr) Composés modulant le calcium intracellulaire
AU2007257423A8 (en) Purine analogs
WO2007112084A8 (fr) Procédé permettant de moduler la croissance de cellules souches hématopoïétiques
EP2068875A4 (fr) Compositions et procédés destinés à moduler l&#39;activité de la sirtuine
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MY148253A (en) Azaadamantane derivatives and methods of use
IL185180A0 (en) Methods and compositions for modulating tweak and fn14 activity
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
UA113397C2 (xx) Попередження несприятливих ефектів, спричинених специфічними доменами зв&#39;язування cd3
WO2009035818A8 (fr) Composés modulant le calcium intracellulaire
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2008058269A3 (fr) Composés et méthodes permettant de moduler l&#39;acheminement des protéines
WO2009051660A3 (fr) Composés permettant l&#39;activation de la signalisation tgf-bêta
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
WO2009091815A3 (fr) Procédés pour moduler de nouveau une lipogenèse hépatique par modulation de l&#39;activité xbp-1
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2011034962A3 (fr) Composés qui modulent le calcium intracellulaire
WO2007120815A3 (fr) Procedes destines au traitement de troubles lymphocytaires par modulation de l&#39;activite siglec
WO2009037542A3 (fr) Composés spirocycliques en tant qu&#39;inhibiteurs de stéaroyle coa désaturase
WO2008088820A3 (fr) Antagonistes de récepteur de glutamate et procédés d&#39;utilisation